Neuralink expands to UK, UAE, and Canada — first patient in UK controls computer within hours of surgery
Summary
In 2025, Neuralink launched clinical trials in three new countries: the GB-PRIME study at University College London Hospitals and Newcastle Hospitals (UK), the UAE-PRIME study at Cleveland Clinic Abu Dhabi, and Canadian procedures at Toronto's University Health Network. The first UK participant, referred to as Paul, successfully controlled a computer with his thoughts within hours of receiving the N1 implant — a demonstration that made international headlines.
Why it matters
Neuralink becoming a multinational clinical program — UK, UAE, Canada, and USA — in a single year transforms the BCI competitive landscape. Multi-jurisdiction data strengthens regulatory submissions and the UAE partnership signals Gulf state interest in being early adopters of frontier neurotechnology.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial